| Date Filed | Type | Description |
| 08/14/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 07/21/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 07/10/2023 |
SC 13G
| Paradigm Biocapital Advisors LP reports a 5.8% stake in Autolus Therapeutics plc |
| 05/15/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 05/11/2023 |
SC 13G
| Paradigm Biocapital Advisors LP reports a 5.4% stake in Viridian Therapeutics, Inc. |
| 02/24/2023 |
SC 13G
| Paradigm Biocapital Advisors LP reports a 5.4% stake in Bicycle Therapeutics plc |
| 02/14/2023 |
SC 13G/A
| Paradigm Biocapital Advisors LP reports a 4.7% stake in Viridian Therapeutics Inc. |
| 02/14/2023 |
SC 13G/A
| Paradigm Biocapital Advisors LP reports a 0% stake in Oyster Point Pharma, Inc. |
| 02/14/2023 |
SC 13G/A
| Paradigm Biocapital Advisors LP has filed a Schedule 13D for ALPINE IMMUNE SCIENCES, INC. |
| 02/14/2023 |
SC 13G/A
| Paradigm Biocapital Advisors LP reports a 9.9% stake in Vor Biopharma Inc. |
| 02/14/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 10/27/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 10/03/2022 |
SC 13G
| Paradigm Biocapital Advisors LP reports a 5% stake in Alpine Immune Sciences, Inc. |
| 08/15/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 07/18/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 05/16/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/14/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/14/2022 |
SC 13G
| Paradigm Biocapital Advisors LP reports a 5.6% stake in Viridian Therapeutics Inc. |